{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-108914","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.415293+00:00","generated_at":"2026-05-30T13:52:57.689948+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elanco presents Zenrelia study showing similar serologic response; approved in Canada","bullets":["Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.","No serious adverse events observed; supports safety of Zenrelia concurrent with core booster vaccinations including rabies.","Zenrelia (ilunocitinib) received regulatory approval in Canada; further details on Health Canada Drug Product Database."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-108914","json":"https://secwatch.observer/filing/0001104659-24-108914.json","markdown":"https://secwatch.observer/filing/0001104659-24-108914.md","text":"https://secwatch.observer/filing/0001104659-24-108914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/0001104659-24-108914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465924108914/tm2425466d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:52:57.689948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}